Monashee Investment Management LLC Makes New $1.29 Million Investment in NewAmsterdam Pharma (NASDAQ:NAMS)

Monashee Investment Management LLC purchased a new stake in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm purchased 50,000 shares of the company's stock, valued at approximately $1,285,000. Monashee Investment Management LLC owned approximately 0.05% of NewAmsterdam Pharma as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently modified their holdings of the company. JPMorgan Chase & Co. boosted its holdings in shares of NewAmsterdam Pharma by 176.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 22,351 shares of the company's stock valued at $371,000 after acquiring an additional 14,280 shares during the last quarter. State Street Corp lifted its holdings in NewAmsterdam Pharma by 168.7% in the third quarter. State Street Corp now owns 37,915 shares of the company's stock valued at $629,000 after acquiring an additional 23,805 shares during the last quarter. Legal & General Group Plc boosted its position in shares of NewAmsterdam Pharma by 24.8% during the fourth quarter. Legal & General Group Plc now owns 22,946 shares of the company's stock worth $590,000 after buying an additional 4,556 shares during the period. American Century Companies Inc. acquired a new stake in NewAmsterdam Pharma during the 4th quarter worth approximately $8,907,000. Finally, Geode Capital Management LLC increased its holdings in NewAmsterdam Pharma by 1.6% in the third quarter. Geode Capital Management LLC now owns 86,322 shares of the company's stock valued at $1,433,000 after buying an additional 1,399 shares during the last quarter. Hedge funds and other institutional investors own 89.89% of the company's stock.

NewAmsterdam Pharma Stock Up 1.1 %

NAMS traded up $0.22 during trading on Monday, reaching $20.25. 192,681 shares of the company's stock were exchanged, compared to its average volume of 601,327. NewAmsterdam Pharma has a fifty-two week low of $14.06 and a fifty-two week high of $27.29. The business has a 50 day moving average price of $19.68 and a 200 day moving average price of $21.25. The company has a market capitalization of $2.22 billion, a P/E ratio of -7.82 and a beta of -0.01.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last released its earnings results on Wednesday, February 26th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The firm had revenue of $12.77 million during the quarter, compared to the consensus estimate of $3.30 million. As a group, research analysts forecast that NewAmsterdam Pharma will post -1.75 EPS for the current year.

Insider Activity

In other NewAmsterdam Pharma news, Director James N. Topper purchased 1,135 shares of the company's stock in a transaction on Wednesday, March 26th. The shares were purchased at an average cost of $22.49 per share, with a total value of $25,526.15. Following the completion of the purchase, the director now owns 3,013,569 shares in the company, valued at $67,775,166.81. This represents a 0.04 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Louise Frederika Kooij sold 150,000 shares of the company's stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total transaction of $3,055,500.00. Following the completion of the sale, the chief accounting officer now owns 15,000 shares of the company's stock, valued at approximately $305,550. The trade was a 90.91 % decrease in their position. The disclosure for this sale can be found here. 19.50% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts have issued reports on NAMS shares. UBS Group set a $41.00 target price on NewAmsterdam Pharma in a research report on Monday, March 3rd. Royal Bank of Canada reissued an "outperform" rating and issued a $40.00 target price on shares of NewAmsterdam Pharma in a report on Friday, January 24th. HC Wainwright reiterated a "buy" rating and issued a $48.00 price target on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. Needham & Company LLC restated a "buy" rating and set a $42.00 target price on shares of NewAmsterdam Pharma in a research report on Tuesday, April 8th. Finally, Scotiabank lifted their price target on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a "sector outperform" rating in a research report on Thursday, February 27th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $43.33.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.